Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1973)	4/3/2002 9:45:06 AM
From: dalroi	Respond to of 10345

XenoPort Names Paul Goddard Chairman, Appoints Chief Patent Counsel SANTA CLARA, Calif., Apr 3, 2002 /PRNewswire via COMTEX/ -- XenoPort, Inc., a privately held emerging biopharmaceutical company, today announced the election of Paul Goddard, Ph.D., former president and chief executive officer of Elan Pharmaceuticals, the largest division of Elan Corporation, as chairman of the XenoPort Board of Directors. The company also announced the appointment of D. Bryon Miller, former assistant secretary and director of intellectual property of Alza Corporation, as vice president and chief patent counsel. "We are delighted to be able to benefit from the substantial expertise of Paul Goddard, whose experience includes senior management roles at both emerging and established, multinational pharmaceutical firms," said Ronald W. Barrett, Ph.D., XenoPort CEO. Prior to its acquisition by Elan in 1998, Dr. Goddard was chairman and CEO of Neurex Corporation, a biotechnology company focused on the discovery, development and commercialization of products for neurological disease and pain management. Before joining Neurex in 1991, he held various senior management positions at SmithKline Beecham, most recently serving as senior vice president for that company's Far East/Asian businesses. Dr. Goddard is also chairman of AP Pharma and serves as a director on the boards of Onyx Pharmaceuticals, Molecular Devices and Adolor Corporation. He obtained his doctorate from St. Mary's Hospital, London. "Having served on XenoPort's board of directors since June of 2001, my enthusiasm for XenoPort, its ground-breaking science and its excellent team continues to deepen," said Dr. Goddard. "XenoPort technology has the potential to revolutionize the manner in which drug candidates are optimized, and the company has begun to build an impressive pipeline of product opportunities. I am pleased to have the opportunity to expand my role in the continuing growth of the company." "We are also very pleased to welcome D. Byron Miller to the XenoPort management team," said Dr. Barrett. "His significant experience as head of the patent department of Alza, a technology leader in the field of drug delivery, will serve our company well as we continue to strengthen our own intellectual property leadership in the areas of drug engineering and active transport." D. Bryon Miller was employed at Alza from 1988 to the present, where he was responsible for all intellectual property issues affecting the company. Prior to joining Alza, he was an associate at Banner, Birch, McKie and Beckett in Washington DC. He received his J.D. degree from Rutgers University. About XenoPort XenoPort, Inc., based in Santa Clara, California, is a privately held biopharmaceutical company focused on harnessing the body's intrinsic transport systems to improve the oral absorption, distribution and pharmacokinetics of drugs. The company applies an integrated technology platform, consisting of transporter genomics, assay technology, and proprietary chemistries, to engineer drug molecules for active transport. XenoPort is currently applying its technology to off-patent drugs to provide new patentable compounds with improved medicinal properties; and the company plans to work collaboratively with pharmaceutical companies to improve the pharmacokinetic properties of their proprietary drug candidates.

To: Icebrg who wrote (1973)	4/3/2002 9:59:33 AM
From: Icebrg	Respond to of 10345

Wednesday April 3, 9:51 am Eastern Time Spectral Diagnostics Reports Positive Mtg With US FDA TORONTO -(Dow Jones)- At a planning meeting between Spectral Diagnostics Inc. (T.SDI) and the U.S. Food & Drug Administration regarding the ongoing regulatory process for the Endotoxin Activity Assay, or EAA, the FDA agreed to a submission path for the EAA as a 510(k) -de novo classification process. In a news release, Spectral said this submission will describe the use of the EAA to risk-stratify patients in the Intensive Care Unit for the development of severe sepsis. It said it's "very pleased that the FDA has agreed to consider this pathway to regulatory approval for the EAA," noting the move represents a positive step towards bringing the EAA to market in the U.S. Spectral's joint-venture partner is Elan Corp. (ELN). The company said it's particularly pleased "that the FDA has accepted that the submission be based on clinical data from the already completed MEDIC trial." Spectral, which develops technologies for comprehensive disease management, said there are more than 750,000 cases of sepsis in the ICU each year in the U.S. alone.